According to STAT, FDA is set to modify its policies to reflect a new expectation: just one pivotal trial will be sufficient for new drug applications (NDA), not two. While two studies may be required in some cases, it would become the exception, not the rule. The agency has yet to formally announce the change. Commissioner Marty Makary told the outlet that the agency “will also…
